AZN•benzinga•
J&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study
Summary
Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line EGFR-mutated NSCLC over osimertinib.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 26, 2025 by benzinga